IP Library Granted Patent US 7,001,885
Granted Patent B2
US 7,001,885 · App. 10/175,382 · Granted Feb 21, 2006

Method for removing multimers of human serum albumin

Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,001,885
App. No.
10/175,382
Granted
Feb 21, 2006
Kind
B2
Abstract

Multimers of human serum albumin are removed from a solution of human serum albumin containing the multimers by bringing the human serum albumin solution into contact with an anion-exchanger equilibrated with a buffer containing a salt in a concentration ranging from 10 to 150 mM and having a pH value ranging from 5 to 9.5.

Claims (10)

1. A method for purifying a recombinant human serum albumin monomer from its multimers, comprising:

(1)treating a recombinant human serum albumin solution at pH 9.0 to convert the multimers of recombinant human serum albumin into monomers, and

(2) loading treated recombinant human serum albumin solution onto an anion-exchange column equilibrated with a buffer with a concentration range from 5 to 200 mM containing added salt concentration ranging from 50 to 100 mM an having a pH value from 6.0 to 7.0 and recovering all of the fractions passed through the column without undergoing absorption.

2. The method of claim 1 , wherein the salt concentration in the buffer in (2) ranges from 50 to 75 mM.

3. The method of claim 1 , wherein the purity of the recombinant human serum albumin in the recombinant human serum albumin solution to be treated is not less than about 85%.

4. The method of claim 2 , wherein the purity of the recombinant human serum albumin in the recombinant human serum albumin solution to be treated is not less than about 85%.

5. The method of claim 2 , wherein the salt is an alkali metal chloride.

6. The method of claim 2 , wherein the salt is sodium chloride.

7. The method of claim 2 , wherein the salt is potassium chloride.

8. The method of claim 1 wherein the buffer has a concentration range of 10–100 mM.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 049245/0561 →
CHANGE OF NAME Recorded May 21, 2019
From: JURIDICAL FOUNDATION, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 049247/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2002
From: ADACHI, SATOSHI; MIZOKAMI, HIROSHI; TAJIMA, YOSHITAKA; MIYATSU, YOSHINOBU; NOUCHI, TOSHINOBU; USHIO, YOSHITAKA
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 013040/0847 →
Priority Claims (1)
JP 2000-324029 · Oct 24, 2000 · national
Continuity (2)
Continuation PCTJP010933500 · Oct 24, 2001
Related Publication 20020183492A1 · Dec 5, 2002